Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Nab-paclitaxel has demonstrated to be an active agent in breast cancer and probably a less
toxic alternative to solvent based taxanes. It is indicated in metastatic breast cancer after
failure of anthracyclines. However, most patients receive anthracyclines as well as taxanes
as part of their (neo-)adjuvant therapy. There is currently no standard treatment for
patients with an early relapse (<12 months) after a taxane containing (neo-)adjuvant therapy.
Nab-paclitaxel, a novel nano-particle encapsulated paclitaxel is expected to have only
limited cross-resistant to solvent-based taxanes and might therefore be indicated in this
setting.